Skip to content

Flocarmed: what changed

BE 0785.951.210NACE 86.210, General medical practiceOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€19,524
2024 · €24,657-€5,133
Equity
€2,000
2024 · €38,782-€36,782
Cash
€57,333
2024 · €27,647+€29,685
Balance sheet total
€78,546
2024 · €57,447+€21,099

Largest movements

2024 to 2025
Assets
  • Cash +€29,685

    up €29,685 (+107%), from €27,647 to €57,333

    mainly Other debts (+€53,652) and Net result for the year (+€19,524)

  • Receivables within one year -€6,398

    down €6,398 (-31.4%), from €20,361 to €13,963

    of which Other amounts receivable: -€6,517

  • Deferred charges and accrued income -€1,932

    down €1,932 (-47.1%), from €4,106 to €2,174

Equity and liabilities
  • Other debts +€53,652

    up €53,652 (+441%), from €12,157 to €65,810

  • Profit (loss) carried forward -€36,782

    no longer reported in 2025 (was €36,782)

  • Tax, wage and social debts +€2,777

    up €2,777 (+42.9%), from €6,473 to €9,250

  • Trade debts +€1,445

    new in 2025: €1,445

Income statement
  • Gross operating margin -€5,834

    down €5,834 (-16.7%), from €34,984 to €29,150

  • Taxes -€2,043

    down €2,043 (-27.2%), from €7,523 to €5,480

  • Financial charges +€934

    up €934 (+74.7%), from €1,251 to €2,184

  • Depreciation +€415

    up €415 (+39.7%), from €1,047 to €1,463

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €24,657
Gross operating margin -€5,834
Depreciation -€415
Other operating charges +€7
Financial income -€0
Financial charges -€934
Taxes +€2,043
Result 2025 €19,524
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€87,199
Investment -€1,207
Financing -€56,306
Cash 2024 €27,647
Net result for the year +€19,524
Depreciation +€1,463
Receivables within one year +€6,398
Deferred charges and accrued income +€1,932
Trade debts +€1,445
Tax, wage and social debts +€2,777
Other debts +€53,652
Accrued charges and deferred income +€8
Investment in fixed assets (net) -€1,207
Contributions, distributions and other -€56,306
Cash 2025 €57,333
brings cash intakes cash out
Every line side by side 35 lines
Line Code 2024 2025 Change %
Total assets 20/58 €57,447 €78,546 +€21,099 +36.7%
Fixed assets 21/28 €5,332 €5,077 -€256 -4.8%
Tangible fixed assets 22/27 €5,332 €5,077 -€256 -4.8%
Plant, machinery and equipment 23 €1,918 €1,411 -€507 -26.4%
Furniture and vehicles 24 €3,414 €3,666 +€252 +7.4%
Current assets 29/58 €52,115 €73,470 +€21,355 +41.0%
Amounts receivable within one year 40/41 €20,361 €13,963 -€6,398 -31.4%
Trade receivables 40 €3,083 €3,201 +€118 +3.8%
Other amounts receivable 41 €17,279 €10,762 -€6,517 -37.7%
Cash at bank and in hand 54/58 €27,647 €57,333 +€29,685 +107%
Deferred charges and accrued income 490/1 €4,106 €2,174 -€1,932 -47.1%
Total equity and liabilities 10/49 €57,447 €78,546 +€21,099 +36.7%
Equity 10/15 €38,782 €2,000 -€36,782 -94.8%
Contributions 10/11 €2,000 €2,000 = 0.0%
Profit (loss) carried forward 14 €36,782 - -€36,782
Amounts payable 17/49 €18,664 €76,546 +€57,882 +310%
Amounts payable within one year 42/48 €18,631 €76,504 +€57,874 +311%
Trade debts 44 - €1,445 +€1,445
Suppliers 440/4 - €1,445 +€1,445
Taxes, remuneration and social security 45 €6,473 €9,250 +€2,777 +42.9%
Taxes 450/3 €6,473 €9,250 +€2,777 +42.9%
Other amounts payable 47/48 €12,157 €65,810 +€53,652 +441%
Accrued charges and deferred income 492/3 €34 €42 +€8 +24.6%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €1,047 €1,463 +€415 +39.7%
Other operating charges 640/8 €506 €499 -€7 -1.3%
Gross operating margin 9900 €34,984 €29,150 -€5,834 -16.7%
Operating profit (loss) 9901 €33,431 €27,188 -€6,243 -18.7%
Financial income 75/76B €0 - -€0
Recurring financial income 75 €0 - -€0
Financial charges 65/66B €1,251 €2,184 +€934 +74.7%
Recurring financial charges 65 €1,251 €2,184 +€934 +74.7%
Profit (loss) for the period before taxes 9903 €32,180 €25,004 -€7,177 -22.3%
Income taxes 67/77 €7,523 €5,480 -€2,043 -27.2%
Profit (loss) for the period 9904 €24,657 €19,524 -€5,133 -20.8%
Profit (loss) for the period to be appropriated 9905 €24,657 €19,524 -€5,133 -20.8%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€63,778 to €88,890

Midpoint €74,242 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Adjusted equity €2,000
Capitalised earnings €125,557 to €175,780
Indication €63,778 to €88,890

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€2,000
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€2,000

Capitalised earnings

net result for the year (9904)
2025
€19,524
2024
€24,657
2023
€8,555
2022
€6,063
Average result
€17,578
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€125,557 / €146,483 / €175,780

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 15 November 2026 via checked.be.